BeiGene announces FDA approval of Tevimbra
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 27 2024
0mins
Should l Buy ?
FDA Approval for Tevimbra: BeiGene, soon to be renamed BeOne Medicines, received FDA approval for Tevimbra in combination with chemotherapy for treating unresectable or metastatic HER2-negative gastric cancer in adults expressing PD-L1.
Monotherapy Approval and Additional Application: Tevimbra is also approved as a standalone treatment for metastatic esophageal squamous cell carcinoma after prior chemotherapy, with an additional application under review for first-line treatment of advanced ESCC.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
